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Validation of an association between the UGT1A6_19_T>G (rs6759892) polymorphism
and overall breast cancer risk. A pilot study included two population-based case-control
studies from Germany (MARIE-GENICA). An independent validation study comprised four
independent breast cancer case-control studies from Finland (KBCP, OBCS), Germany
(BBCC), and Sweden (SASBAC). The pooled analysis included 7418 cases and 8720
controls from all six studies. Participants were of European descent. Genotyping was
done by MALDI-TOF MS and statistical analysis was performed by logistic regression
adjusted for age and study. The increased overall breast cancer risk for women with
the UGT1A6_19_GG genotype which was observed in the pilot study was confirmed in
the set of four independent study collections (OR 1.13, 95% CI 1.05–1.22; p = 0.001).
The pooled study showed a similar effect (OR 1.09, 95% CI 1.04–1.14; p = 0.001). The
risk effect on the basis of allele frequencies was highly significant, the pooled analysis
showed an OR of 1.11 (95% CI 1.06–1.16; p = 5.8 × 10−6). We confirmed the association
of UGT1A6_19_GG with increased overall breast cancer risk and conclude that our result
from a well powered multi-stage study adds a novel candidate to the panel of validated
breast cancer susceptibility loci.
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INTRODUCTIONS
Many breast cancer genes have been identified including BRCA1,
BRCA2, TP53, ATM, CHEK2, BRIP1 and PALB2 which are
causative for hereditary breast cancers (Narod et al., 1995; Ford
et al., 1998; Easton et al., 2007). Moreover, more than 20 common
genetic variants have been shown to contribute to breast cancer
risk; among these, the fibroblast growth factor receptor 2 (FGFR2)
polymorphism rs2981582 as well as loci close to the cell cycle reg-
ulator Cyclin D1 (CCND1) at 11q13 are the most prominent risk
loci (Easton et al., 2007; Lambrechts et al., 2012). Most of these
loci have been identified by genome-wide association studies
(GWAS) (Easton et al., 2007; Turnbull et al., 2010; Lambrechts
et al., 2012). However, a shortcoming of this powerful approach
is the lack of a sufficient coverage of polymorphisms in gene
regions with high sequence similarities to other genes or pseudo
genes. Genetic variations in such gene regions require an adapted
primer design and amplification conditions which allow specific
genotyping of the loci of interest (Justenhoven et al., 2010; The
MARIE-GENICA Consortium, 2010). Therefore, polymorphic
loci in homologous sequences are usually exempted from GWAS
arrays, and can be analyzed in specially designed low-plex geno-
typing assays or small scale microarrays, e.g., the AmpliChip®
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CYP450 Test (Roche Diagnostic GmbH, Germany), the DMET™
Plus Solution (Affymetrix Inc. CA, USA) or the VeraCode®
ADME Core Panel (Illumina, Inc. CA, USA) (Justenhoven, 2012).
Sequence similarities are rather common among genes cod-
ing for phase I and II enzymes as well as transporters, for
example P450 cytochrome 3A (CYP3A) genes with more than
70% homology (Filipits et al., 1999; Domanski et al., 2001),
the UDP glucuronosyl transferases 1 (UGT1) genes with more
than 50% homology (Gong et al., 2001) and the solute car-
rier organic anion transporter (SLCO) genes with more than
40% homology (Hagenbuch and Meier, 2004). It is of note, that
these enzymes and transporters play an elementary role in the
evolutionary-conserved detoxification system and in the home-
ostasis of endogenous molecules (Nebert, 1991; Goldstone et al.,
2006).
In light of known effects of toxic compounds and steroid hor-
mones on breast carcinogenesis, these enzymes and transporters
are prime candidates for the investigation of their contribution
to breast cancer risk (The MARIE-GENICA Consortium, 2010;
Justenhoven et al., 2011). Thus, the UGTs are of particular interest
because glucuronidation represents a major route of detoxifica-
tion and elimination of xenobiotics including drugs and endobi-
otics (Bock and Kohle, 2005). UGT1A6 is the founding member
of the UGT1 gene family and mediates the inactivation of pheno-
lic compounds, e.g., 4-ethylphenol, acetaminophen or estradiol
(Harding et al., 1988; Orzechowski et al., 1994; Raftogianis et al.,
2000; Bock and Kohle, 2005). Two non-synonymous polymor-
phisms UGT1A6_19_T>G (rs6759892) and UGT1A6_541_A>G
(rs2070959) are located in exon 1 causing amino acid exchanges
from serine to alanine at position 7 and threonine to ala-
nine at position 181, respectively [GenBank: P19224]. The vari-
ant alleles have been associated with decreased activity of the
UGT1A6 enzyme (Ciotti et al., 1997). We previously reported
their possible effect on breast cancer risk in two population-
based case-control studies from Germany (The MARIE-GENICA
Consortium, 2010). To validate the roles of UGT1A6 polymor-
phisms in breast cancer risk we conducted an independent con-
firmatory study and a pooled analysis with more than 7000
patients and 8000 controls, and report the association between
the UGT1A6_19_GG genotype and an increased overall breast
cancer risk.
MATERIALS AND METHODS
A total of 7148 breast cancer cases and 8472 controls from six
independent cohorts were included in the analysis (Table 1).
Study cohorts were selected on the basis of inclusion of
female cases and controls from European descent, resident in
the same region, unselected, invasive breast cancer cases and
controls without history of breast cancer. Moreover, data on
case-control status, age (age at diagnosis for cases and age
at interview for controls), estrogen receptor (ER) and pro-
gesterone receptor (PR) needed to be available as well as
DNA samples isolated from blood cells. Three studies were
from Germany: the Bavarian Breast Cancer Cases and Controls
Collection (BBCC), the Gene Environment Interactions and
Breast Cancer study (GENICA), and the Mammary Carcinoma
Risk Factor Investigation (MARIE). Two studies were from
Finland: the Kuopio Breast Cancer Project (KBCP) and the
Oulu Breast Cancer Study (OBCS). One study was from Sweden:
the Singapore and Sweden Breast Cancer Study (SASBAC).
All studies were approved by respective ethic committees and
all participants gave written informed consent. Each individ-
ual study provided data on case-control status, age, ER and
PR status as well as ethnicity. All study participants were of
European descent.
Blood-derived DNA samples of all cases and controls were
genotyped for UGT1A6_19_T>G and UGT1A6_541_A>G by
matrix-assisted laser desorption/ionization mass spectrometry
(MALDI-TOF MS; Sequenom, San Diego, CA) as described
previously (The MARIE-GENICA Consortium, 2010). Genetic
analyses included negative controls and 10% randomly selected
duplicate samples for quality control. Call rates were greater
than 98% and repeated analyses of the duplicate samples showed
100% concordance. UGT1A6_19_T>G and UGT1A6_541_A>G
genotype frequencies met the Hardy–Weinberg equilibrium.
Associations between UGT1A6_19_T>G and UGT1
A6_541_A>G genotypes and breast cancer risk were ana-
lyzed by logistic regression adjusted for age and study using
SPSS software v 15.0 (SPSS Inc., IBM Corporation, Somers, NY).
Four subgroup analyses were performed including the analysis
of ER-positive cases vs. controls, ER-negative cases vs. controls,
PR-positive cases versus controls, and PR-negative cases vs.
controls. Risk estimates were calculated as odds ratios (OR) with
95% confidence interval (95% CI) and corresponding p-value.
Power calculation was done by nQuery Advisor® 4.0.
RESULTS
Our validation study had 80% power to detect a mini-
mum OR of 1.06 and 1.07 for the UGT1A6_19_T>G and
UGT1A6_541_A>G polymorphisms, respectively (α = 0.05,
two-sided test). We observed no breast cancer risk association for
the UGT1A6_541_A>G genotypes and none of the two variants
showed an association with tumor ER and PR status (data not
shown).
For the UGT1A6_19_T>G polymorphism, we confirmed an
increased breast cancer risk for women carrying the homozy-
gous variant GG genotype (Table 2). This finding complements
our two-stage study in which carriers of the UGT1A6_19_GG
genotype showed an OR of 1.17 (95% CI 1.03–1.34; p = 0.014)
in the previous pilot investigation (stage 1) (The MARIE-
GENICA Consortium, 2010). This result was based on adjust-
ment for duration of any hormone replacement therapy, type of
menopause, number of births, ever having breastfed, ever hav-
ing smoked, number of mammograms, ever having had benign
breast disease, family history of breast cancer in 1st degree rela-
tives, body mass index, study region, and year of birth in 5 year
categories. Adjustment for age and study only showed a similar
risk effect with an OR of 1.09 (95% CI 1.02–1.16; p = 0.009) for
theUGT1A6_19_GG genotype (Table 2). The confirmation of the
increased overall breast cancer risk of OR 1.13 (95% CI 1.05–1.22;
p = 0.001; Table 2) is reported herein (stage 2 using four inde-
pendent cohorts BBCC, KBCP, OBCS, and SASBAC). The pooled
analysis of BBCC, KBCP, OBCS, SASBAC, GENICA, and MARIE
again confirmed theUGT1A6_19_GG genotype as a breast cancer
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Table 1 | Description of study design for each participating study.





Bavarian Breast Cancer Cases and
Controls (Fasching et al., 2008;
Schrauder et al., 2008)
Germany Consecutive, unselected cases with
invasive breast cancer recruited at the
University Breast Centre, Franconia in
Northern Bavaria during 2002–2006.
Healthy women with no diagnosis of
cancer aged 55 or older. Invited by a
newspaper advertisement in




Gene Environment Interaction and
Breast Cancer in Germany (Pesch
et al., 2005; Justenhoven et al., 2008)
Germany Incident breast cancer cases were
enrolled from 2000 to 2004 from the
Greater Bonn area (from all hospitals
within the study region); cases were
enrolled within 6 months of
diagnosis.
Controls were selected from
population registries from 31
communities in the greater Bonn
area; matched to cases in 5-year age
classes from 2001 to 2004.
23–80/24–80
MARIE:
Mammary Carcinoma Risk Factor
Investigation (Flesch-Janys et al.,
2008)
Germany Incident and prevalent cases
diagnosed from 2001 to 2005 in the
study region Hamburg in Northern




Two controls per case were randomly
drawn from population registries and
frequency matched by birth year and
study region to the case. Controls
were recruited from 2002 to 2006.
50–75/49–75
KBCP:
Kuopio Breast Cancer Project
(Hartikainen et al., 2005, 2006)
Finland Women seen at Kuopio University
Hospital between 1990 and 1995
because of breast lump,
mammographic abnormality, or other
breast symptom who were found to
have breast cancer.
Age and long-term area-of-residence
matched controls selected from the
National Population Register and
interviewed in parallel with the cases.
23–92/27–77
OBCS:
Oulu Breast Cancer Study (Wedren
et al., 2004; Erkko et al., 2007)
Finland Consecutive incident cases
diagnosed at the Oulu University
Hospital between 2000 and 2004.
Healthy, consecutive, anonymous,
female Finnish Red-Cross blood
donors recruited in 2002 from the




Singapore and Sweden Breast
Cancer Study (Wedren et al., 2004)
Sweden Incident cases from 1993 to 1995
identified via the 6 regional cancer
registries in Sweden, to which
reporting is mandatory.
Controls were randomly selected
from the total population registry in
5-year age groups to match the
expected age-frequency distribution
among cases. Patients and controls
were recruited from 1993 to 1995.
50–75/49–76
risk factor with an OR of 1.09 (95% CI 1.04–1.14; p = 0.001;
Table 2).
In addition to the genotype frequencies the risk effect of the
UGT1A6_19_G allele was analyzed on the level of allele frequen-
cies and showed ORs of 1.08 (95% CI 1.01–1.15: p = 0.012), 1.10
(95% CI 1.02–1.18; p = 0.12), and 1.11 (95% CI 1.06–1.16; p =
5.86× 10−6) in the pilot and validation study as well as pooled
analysis, respectively.
DISCUSSION
We confirmed theUGT1A6_19_GG genotype as an overall breast
cancer risk factor, first, in an independent validation study includ-
ing breast cancer cases and controls from Finland, Germany and
Sweden as well as in a pooled analysis of more than 15,000 study
subjects following our initial report from a German pilot study
(The MARIE-GENICA Consortium, 2010). This finding sup-
ports the notion that reduced activity of detoxification enzymes
such as UGT1A6 contribute to an overall breast cancer risk.
The present study highlights the necessity to extend investiga-
tions for the discovery of breast cancer susceptibility loci to
enzymes involved in detoxification processes despite their inher-
ent problem of high homology which excludes them from stan-
dard GWAS approaches. As of yet, although GWAS approaches
have delivered more than 20 common breast cancer risk loci
(Turnbull et al., 2010; Ghoussaini et al., 2012), there is a pos-
sibility, that tailored approaches to cover variants in regions of
sequence homology may add to the growing list of genetic risk
factors.
It is of note that the herein observed ORs for the
UGT1A6_19_G variant are in the range of the so far established
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Table 2 | Association of UGT1A6_19_T>G with breast cancer risk.
Study UGT1A6_19_T>G
genotypes and alleles
Cases (%) Controls (%) OR (95% CI) p-value
PILOT STUDY
MARIE-GENICA TT 1006 (32.0) 1882 (34.4) 1.00a
(The MARIE-GENICA Consortium, 2010) TG 1544 (49.2) 2644 (48.4) 1.10b (0.99–1.21)
GG 589 (18.7) 940 (17.2) 1.17b (1.03–1.34) 0.014c
TT 1134 (32.3) 2017 (34.6) 1.00a
TG 1725 (49.1) 2807 (48.2) 1.10 (0.99–1.21) 0.051
GG 654 (18.6) 1000 (17.2) 1.09 (1.02–1.16) 0.009
TG+GG 2379 3807 1.12 (1.02–1.23) 0.013
T 3556 (56.6) 6408 (58.6) 1.00a
G 2722 (43.4) 4524 (41.4) 1.08 (1.01–1.15) 0.012
VALIDATION STUDY
BBCC, KBCP, OBCS, SASBAC TT 1145 (31.5) 858 (32.4) 1.00a
TG 1643 (45.2) 1269 (47.9) 0.98d (0.87–1.10) 0.686
GG 847 (23.3) 521 (19.7) 1.13d (1.05–1.22) 0.001
TG + GG 2490 1790 1.06d (0.95–1.19) 0.295
T 3933 (54.1) 2987 (62.5) 1.00a
G 3337 (45.9) 1790 (37.5) 1.10 (1.02–1.18) 0.012
POOLED ANALYSIS
MARIE-GENICA, BBCC, KBCP, TT 2279 (31.9) 2875 (33.9) 1.00a
OBCS, SASBAC TG 3368 (47.1) 4076 (48.1) 1.03d (0.96–1.11) 0.418
GG 1501 (21.0) 1521 (18.0) 1.09d (1.04–1.14) 0.001
TG + GG 4869 5597 1.07d (1.00–1.15) 0.041
T 7926 (55.4) 9826 (58.0) 1.00a
G 6370 (44.6) 7118 (42.0) 1.11 (1.06–1.16) 5.86× 10−6
CI, confidence interval; OR, odds ratio.
aReference.
bOR adjusted for duration of any hormone replacement therapy, type of menopause, number of births, ever having breastfed, ever having smoked, number of
mammograms, ever having had benign breast disease, family history of breast cancer in 1st degree relatives, and body mass index, study region and year of birth
in 5 year categories.
cp-value from a log additive model as published.
d OR adjusted for age and study.
common low-penetrance breast cancer susceptibility loci with
ORs from 1.07 to 1.22 including polymorphisms in genes such
as FGFR2 and TOX3. As of yet, this set of more than 20 known
susceptibility loci accounts for about 8% of the heritability of
breast cancer (Ghoussaini et al., 2012). Therefore, it will be of
particular interest to evaluate the UGT1A6 polymorphism in
concert with all known risk factors in large study collections
to establish a more comprehensive breast cancer susceptibility
panel.
We analyzed a potential association of the UGT1A6_19_T>G
polymorphism with ER and PR status of breast tumors and
observed no effect. Other histopathological variables were not
included in the analyses herein due to missing data and variables
as well as differences in the collection and documentation of these
variables among studies. Since breast cancer is a heterogeneous
disease it will be of interest to analyze the association of this poly-
morphism and breast cancer subtypes in large study collections
with a broad set of hisopathological variables.
The role of a UGT1A6 variant for breast cancer risk is reason-
able because a reduction of enzyme activity has been previously
suggested (Ciotti et al., 1997). Moreover, it is well known that
UGT1A6 is involved in the conjugation of steroid hormones
(Raftogianis et al., 2000) and increased levels of sex hormones
are a known risk factor for breast cancer (Key et al., 2002).
UGT1A6 also conjugates exogenous compounds which occur in
the environment and in food, e.g., 4-ethylphenol or in drugs,
e.g., acetaminophen (Harding et al., 1988; Bock and Kohle, 2005),
which together with other UGT1A6 substrates have been sug-
gested to affect breast cancer risk (Friis et al., 2008; Chen et al.,
2011).
CONCLUSION AND PERSPECTIVES
The present study which is limited to women of European descent
holds the potential for further validation of the UGT1A6 and
other functionally related enzymes in a more in-depth global con-
text. Currently, we consider the prediction of breast cancer risk by
polymorphisms of phase I and II enzymes in its initial stage and
encourage further comprehensive studies to establish their con-
tributory role in breast cancer risk. This should be done across
populations and ethnicities as is potentially accessible through
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the Breast Cancer Association Consortium (BCAC) (Easton et al.,
2007; Lambrechts et al., 2012). Notably, our finding expands the
scope of known crucial pathways involved in breast cancer suscep-
tibility from growth and cell cycle control to metabolic enzymes
and confirms the link between the phase II enzyme UGT1A6 and
breast cancer risk.
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